View Exam | PowerPak

1. Why is it important for pharmacists to engage in a team approach to help close the gaps in CKD treating treatment?

A. A shortage of nephrologists exists in the United States B. CKD has a high symptom burden C. Treatment guidelines are clear, concise, and readily available D. Computerized order entry exists for chronic medications

2. Which of the following drug therapies is first-line treatment for a patient with CKD associated with T2D, BP 142/62 mmHg, eGFR 42 mL/ min, serum K 4.8 meq/L, and UACR 652 mg/g creatinine?

A. Losartan 100 mg/d B. Canagliflozin 100 mg/d C. Finerenone 10 mg/d D. HCTZ 100 mg once daily

3. Regarding FIDELIO-DKD, which evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA) in CKD patients with T2D:

A. Inclusion criteria included patients receiving maximum-tolerated doses of an ACE inhibitor or ARB B. Although investigator-reported hyperkalemia was increased, the clinical impact was minimal C. Finerenone significantly reduced the primary kidney-specific composite endpoint D. Finerenone significantly reduced the secondary cardio-specific composite endpoint E. All of the above are correct statements

4. The 2021 Kidney Disease Improved Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in CKD suggests that adults with high blood pressure and CKD be treated with a target systolic blood pressure (if tolerated) of:

A. < 110 mm Hg B. < 120 mm Hg C. < 130 mm Hg D. < 140 mm Hg

5. Which components of the new Centers for Medicare and Medicaid Services Innovation (CMMI) Kidney Care models present new opportunities for pharmacists to become involved in the care of patients with kidney diseases?

A. Value-based components B. Performance-based components that will be enhanced with optimal medication management C. Benefit enhancements (kidney disease education and post-discharge home visits) D. All of the above

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Why is it important for pharmacists to engage in a team approach to help close the gaps in CKD treating treatment?

2. Which of the following drug therapies is first-line treatment for a patient with CKD associated with T2D, BP 142/62 mmHg, eGFR 42 mL/ min, serum K 4.8 meq/L, and UACR 652 mg/g creatinine?

3. Regarding FIDELIO-DKD, which evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA) in CKD patients with T2D:

4. The 2021 Kidney Disease Improved Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in CKD suggests that adults with high blood pressure and CKD be treated with a target systolic blood pressure (if tolerated) of:

5. Which components of the new Centers for Medicare and Medicaid Services Innovation (CMMI) Kidney Care models present new opportunities for pharmacists to become involved in the care of patients with kidney diseases?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Why is it important for pharmacists to engage in a team approach to help close the gaps in CKD treating treatment?

2. Which of the following drug therapies is first-line treatment for a patient with CKD associated with T2D, BP 142/62 mmHg, eGFR 42 mL/ min, serum K 4.8 meq/L, and UACR 652 mg/g creatinine?

3. Regarding FIDELIO-DKD, which evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA) in CKD patients with T2D:

4. The 2021 Kidney Disease Improved Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in CKD suggests that adults with high blood pressure and CKD be treated with a target systolic blood pressure (if tolerated) of:

5. Which components of the new Centers for Medicare and Medicaid Services Innovation (CMMI) Kidney Care models present new opportunities for pharmacists to become involved in the care of patients with kidney diseases?

« Return to Activity

Customers who Purchased
this Activity also Purchased